Top pharma firms hike complex drug R&D spend to Rs 8,500 crore in 2015-16, eye buyouts Industry-The Economic Times — December 16, 2016 comments off Experts predict the launch pipelines for generic players in the US will be impacted as drugs coming off patent may see a fall in the 2017-2020 period.
Experts predict the launch pipelines for generic players in the US will be impacted as drugs coming off patent may see a fall in the 2017-2020 period.